How to buy Purple Biotech stock (PPBT)

Purple Biotech is a biotechnology business based in the US. Purple Biotech shares (PPBT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.42 – a decrease of 10.7% over the previous week. Purple Biotech employs 20 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Purple Biotech stock

Buy Purple Biotech stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Purple Biotech stock price (NASDAQ: PPBT)

Use our graph to track the performance of PPBT stocks over time.

Purple Biotech shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$3.42
52-week range	$2.00 - $20.60
50-day moving average more info button	$3.68
200-day moving average more info button	$8.41
Wall St. target price	$33.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-8.10

Is it a good time to buy Purple Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Purple Biotech price performance over time

Historical closes compared with the close of $3.45 from 2024-12-19

1 week (2024-12-13)	-9.92%
1 month (2024-11-21)	35.83%
3 months (2024-09-20)	-49.93%
6 months (2024-06-21)	599.80%

1 year (2023-12-21)	306.22%
2 years (2022-12-21)	-89.08%
3 years (2021-12-21)	82.8
5 years (2019-12-20)	148

Purple Biotech financials

Gross profit TTM	$-120,000
Return on assets TTM	-29.25%
Return on equity TTM	-44.67%
Profit margin	0%
Book value	$0.14
Market Capitalization more info button	$9.4 million

TTM: trailing 12 months

Purple Biotech share dividends

We're not expecting Purple Biotech to pay a dividend over the next 12 months.

Have Purple Biotech's shares ever split?

Purple Biotech's shares were split on a 1:20 basis on 16 September 2024 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Purple Biotech shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Purple Biotech shares which in turn could have impacted Purple Biotech's share price.

Purple Biotech share price volatility

Over the last 12 months, Purple Biotech's shares have ranged in value from as little as $2 up to $20.6. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Purple Biotech's is 0.384. This would suggest that Purple Biotech's shares are less volatile than average (for this exchange).

Purple Biotech overview

Purple Biotech Ltd. , a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

Frequently asked questions

What percentage of Purple Biotech is owned by insiders or institutions?
Currently 2.865% of Purple Biotech shares are held by insiders and 9.333% by institutions. How many people work for Purple Biotech?
Latest data suggests 20 work at Purple Biotech. When does the fiscal year end for Purple Biotech?
Purple Biotech's fiscal year ends in December. Where is Purple Biotech based?
Purple Biotech's address is: 4 Oppenheimer Street, Rehovot, Israel, 7670104 What is Purple Biotech's ISIN number?
Purple Biotech's international securities identification number is: US74638P1093